Main Content

Press Release
WKR: Elekta receives FDA clearance for Elekta Synergy (TM)

PRESS RELEASE Stockholm, 28October 2003
Images available – see below!

ELEKTA RECEIVES FDA CLEARANCEFOR ELEKTA SYNERGY™

The revolutionary newradiotherapy system from Elekta is first to combine x-ray volumeimaging and treatment in a single platform

On Monday the 27 October, the U.S.Food and Drug Administration (FDA), granted 510(k) pre-marketclearance to the Elekta Synergy™ System from Elekta. Thismeans that Elekta can now market and sell the system also in theU.S. In Europe, Elekta Synergy™ is already marketed,following CE marking in July 2003.

In research and development overthe last five years, this new radiotherapy treatment platformdirectly addresses the two most persistent and significantproblems in modern radiation therapy: internal organ motion anderrors in patient set-up.

Elekta was the first vendor tostart research on image-guided radiation therapy, the first tohave systems in clinical use, and the first to bring thesesolutions to the market.

"With the introduction ofElekta Synergy™, Elekta is leading the efforts to increasethe precision of radiotherapy delivery by limiting or eveneliminating the impact of the patient’s internal organmotion and how the patient is set up for treatment from day today", says Peter J. Gaccione, vice president Oncology Salesand Service Operations for Elekta North America.

Elekta Synergy™ does this byusing innovative x-ray volume imaging technology that isintegrated directly onto the treatment system itself. This meansthat routine pre-treatment imaging of a tumor can now beperformed immediately prior to treatment, decreasing the riskthat a tumor or internal organs will change position. Inaddition, since the patient doesn’t have to be moved from animaging device (e.g. MR, CT) to the radiotherapy treatmentmachine, the problem of errors from patient re-setup areeliminated.

The first use of this new class ofImage Guided Radiation Therapy (IGRT) technology took place atthe Netherlands Cancer Institute (NKI) in July 2003, when threecancer patients were treated using the Elekta Synergy™system. In addition to NKI, three other leading cancer clinics inGreat Britain, Canada and USA have research installations ofElekta Synergy™.

Clinical data presented both atthe recent ASTRO annual meeting in the U.S. and the EuropeanESTRO meeting, demonstrate the enormous potential for the newElekta Synergy™ system to significantly advanceradiotherapy treatment for cancer patients.

It has been shown that bycombining an X-ray volume imaging system and radiotherapyequipment (a medical accelerator) to provide ‘real time’images of the tumour during treatment, the image quality andtreatment accuracy is significantly improved. (ref:1,2)

Volker Stieber, Elekta’sExecutive Vice President – Technology Development &Operations, acknowledged the aptness of the new product’sname, "Synergy is defined as two or more entities workingtogether, wherein the sum is greater than each individual’scontribution. Elekta Synergy™ adds dedicated imagingtechnology to a proven treatment platform, creating a system thatis truly more than the sum of its parts."

Investor inquiries:
International: Peter Ejemyr, Group VP CorporateCommunications, Elekta AB (publ),
Phone: +46 8 587 254 00, e-mail: peter.ejemyr@elekta.com
United States: Lars Jonsteg, VP Investor Relations North America,Elekta, USA
Phone: +1 770-670-2419, e-mail: lars.jonsteg@elekta.com

Press contact U.S:
Michelle Lee, PR and Advertising Manager
michelle.lee@elekta.com
Tel: +1 770-300-9725 x 277, Fax: +1 770-448-6338

Notes to editors:
• For further information regarding Elekta Synergy™and other Elekta products, please visit www.elekta.com
• Images of Elekta Synergy™ can be accessed at thefollowing website address: www.elekta.com/investors

About Elekta:
Elekta is a world-leading supplier of advanced andinnovative radiation oncology and neurosurgery solutions andservices for precise treatment of cancer and brain disorders.Elekta's solutions are clinically effective, cost efficient andgentle to the patient.

References:
1. Oldham M, et al. Online volumetric CT-guidedradiation therapy. Abstract 101. American Society for TherapeuticRadiology and Oncology Annual Meeting, October 2003.
2. Letourneau D, et al. Implementation of an on-board kilovoltagecone-beam CT imaging system for clinical applications. Abstract102. American Society for Therapeutic Radiology and OncologyAnnual Meeting 2003.


This information was brought to you by Waymaker http://www.waymaker.net

The following files are available for download: